170 related articles for article (PubMed ID: 36099589)
1. Mastoid Obliteration Using S53P4 Bioactive Glass in Cholesteatoma Surgery: A 10-Year Single-Center Experience in 173 Adult Patients with Long-Term Magnetic Resonance Imaging Controlled Follow-up.
Kroon VJ; Mes SW; Borggreven PA; van de Langenberg R; Colnot DR; Quak JJ
Otol Neurotol; 2022 Dec; 43(10):1181-1188. PubMed ID: 36099589
[TBL] [Abstract][Full Text] [Related]
2. Cholesteatoma surgery in the pediatric population: remaining challenges in the era of mastoid obliteration.
Kroon VJ; Mes SW; Borggreven PA; van de Langenberg R; Colnot DR; Quak JJ
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1713-1722. PubMed ID: 36208330
[TBL] [Abstract][Full Text] [Related]
3. Recidivous cholesteatoma: DWI MR after canal wall up and canal wall down mastoidectomy.
Bakaj T; Zbrozkova LB; Salzman R; Tedla M; Starek I
Bratisl Lek Listy; 2016; 117(9):515-520. PubMed ID: 27677195
[TBL] [Abstract][Full Text] [Related]
4. Mastoid obliteration with S53P4 bioactive glass in cholesteatoma surgery.
de Veij Mestdagh PD; Colnot DR; Borggreven PA; Orelio CC; Quak JJ
Acta Otolaryngol; 2017 Jul; 137(7):690-694. PubMed ID: 28125327
[TBL] [Abstract][Full Text] [Related]
5. Mastoid obliteration with S53P4 bioactive glass after canal wall down mastoidectomy: Preliminary results.
Król B; Cywka KB; Skarżyńska MB; Skarżyński PH
Am J Otolaryngol; 2021; 42(2):102895. PubMed ID: 33429176
[TBL] [Abstract][Full Text] [Related]
6. Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients.
Vos J; de Vey Mestdagh P; Colnot D; Borggreven P; Orelio C; Quak J
Eur Arch Otorhinolaryngol; 2017 Dec; 274(12):4121-4126. PubMed ID: 28956143
[TBL] [Abstract][Full Text] [Related]
7. Tolerance and safety of 45S5 bioactive glass used in obliteration procedures during middle ear surgery: Preliminary results.
Al Tamami N; Bawazeer N; Fieux M; Zaouche S; Tringali S
Am J Otolaryngol; 2020; 41(6):102542. PubMed ID: 32620365
[TBL] [Abstract][Full Text] [Related]
8. Bioactive glass granules for mastoid and epitympanic surgical obliteration: CT and MRI appearance.
Bernardeschi D; Law-Ye B; Bielle F; Hochet B; Sterkers O; Dormont D; Pyatigorskaya N
Eur Radiol; 2019 Oct; 29(10):5617-5626. PubMed ID: 30888487
[TBL] [Abstract][Full Text] [Related]
9. Use of bonalive in obliterative mastoidectomy: anatomical results and clinical outcome.
Fassone E; Fabiano B; Caracciolo A; Sapino S; Ferrero V
Eur Arch Otorhinolaryngol; 2023 Aug; 280(8):3577-3583. PubMed ID: 36917252
[TBL] [Abstract][Full Text] [Related]
10. Canal wall up surgery with mastoid and epitympanic obliteration in acquired cholesteatoma.
Hellingman CA; Geerse S; de Wolf MJF; Ebbens FA; van Spronsen E
Laryngoscope; 2019 Apr; 129(4):981-985. PubMed ID: 30408197
[TBL] [Abstract][Full Text] [Related]
11. Surgical management of middle ear cholesteatoma in children with Turner syndrome: a multicenter experience.
Zanetti D; Di Lella F; Negri M; Vincenti V
Acta Biomed; 2018 Oct; 89(3):382-388. PubMed ID: 30333463
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Soft Versus Bony Canal Wall Reconstruction with Mastoid Obliteration.
Vesole AS; Doyle EJ; Sarkovics K; Gharib M; Samy RN
Otol Neurotol; 2024 Jun; 45(5):542-548. PubMed ID: 38511274
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of hearing after cholesteatoma surgery: the bony obliteration tympanoplasty versus canal wall up and canal wall down without mastoid obliteration.
van der Toom HFE; van der Schroeff MP; Metselaar M; van Linge A; Vroegop JL; Pauw RJ
Eur Arch Otorhinolaryngol; 2022 Nov; 279(11):5181-5189. PubMed ID: 35399107
[TBL] [Abstract][Full Text] [Related]
14. Mastoid obliteration with hydroxyapatite vs. bone pâté in mastoidectomy surgery performed on patients with cholesteatoma and chronic suppurative otitis media: a retrospective analysis.
Lindeboom JJ; van Kempen PMW; Buwalda J; Westerlaken BO; van Zuijlen DA; Bom SJH; van der Beek FB
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1703-1711. PubMed ID: 36173443
[TBL] [Abstract][Full Text] [Related]
15. Long-term Results of Troublesome CWD Cavity Reconstruction by Mastoid and Epitympanic Bony Obliteration (CWR-BOT) in Adults.
Vercruysse JP; van Dinther JJ; De Foer B; Casselman J; Somers T; Zarowski A; Cremers CC; Offeciers E
Otol Neurotol; 2016 Jul; 37(6):698-703. PubMed ID: 27023012
[TBL] [Abstract][Full Text] [Related]
16. Canal wall down approach for tympano-mastoid cholesteatoma: long-term results and prognostic factors.
Pareschi R; Lepera D; Nucci R
Acta Otorhinolaryngol Ital; 2019 Apr; 39(2):122-129. PubMed ID: 31097831
[TBL] [Abstract][Full Text] [Related]
17. Canal reconstruction mastoidectomy: Outcomes comparison following primary versus secondary surgery.
Stevens SM; Walters ZA; Babo K; Peddireddy N; Tawfik KO; Samy RN
Laryngoscope; 2019 Nov; 129(11):2580-2587. PubMed ID: 30883762
[TBL] [Abstract][Full Text] [Related]
18. Canal-wall up cholesteatoma surgery with mastoid obliteration leads to lower rates of disease recurrence without affecting hearing outcomes.
Erfurt C; Westerhout SF; Straatman LV; Smit AL; Stokroos RJ; Thomeer HGXM
Front Surg; 2024; 11():1381481. PubMed ID: 38650663
[TBL] [Abstract][Full Text] [Related]
19. Bioglass reconstruction of posterior meatal wall after canal wall down mastoidectomy.
Sorour SS; Mohamed NN; Abdel Fattah MM; Elbary MEA; El-Anwar MW
Am J Otolaryngol; 2018; 39(3):282-285. PubMed ID: 29526381
[TBL] [Abstract][Full Text] [Related]
20. Acquired middle ear cholesteatoma in children with cleft palate: experience from 18 surgical cases.
Vincenti V; Marra F; Bertoldi B; Tonni D; Saccardi MS; Bacciu S; Pasanisi E
Int J Pediatr Otorhinolaryngol; 2014 Jun; 78(6):918-22. PubMed ID: 24690221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
